



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

EHT 1610

Chemical Properties


CAS No. : 1425945-60-3

Formula: C₁₈H₁₄FN₅O₂S

Molecular Weight: 383.4

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	EHT 1610 (EHT 5372) is a potent inhibitor of DYRK, with an IC ₅₀ of 0.36 nM and 0.59 nM for DYRK1A and DYRK1B, respectively. EHT 1610 has an inhibitory effect on leukemia, regulating cell cycle and inducing cell apoptosis.
Targets(IC ₅₀)	GSK-3, NF-κB, Tyrosinase, DYRK, CDK
In vitro	EHT 1610 triggers apoptosis in primary ALL cells that exhibit resistance to cytarabine treatment.[2] EHT 1610 demonstrates a dose-dependent induction of apoptosis in B- and T-cell lines as well as primary human pediatric cells.[2] Treatment with EHT 1610 for a duration of 72 hours leads to the inhibition of DYRK1A, resulting in the disruption of DYRK1A-mediated FOXO1 and STAT3 signaling pathways. This disruption ultimately leads to selective cell death in leukemic B cells.[3] Exposure to EHT 1610 at concentrations ranging from 2.5 to 10 μM for a period of 4-5 hours results in the inhibition of phosphorylation of FOXO1, STAT3, and cyclin D3. This inhibition leads to the regulation of late cell-cycle progression, mitochondrial ROS levels, and DNA damage, respectively.[3]
In vivo	In a murine model of aggressive leukemia, EHT 1610 (20 mg/kg/d; i.p.; twice a day; 3 weeks) demonstrates antileukemia activity when administered intraperitoneally.[3]

Solubility Information

Solubility	DMSO: 4.5 mg/mL (11.7 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

A DRUG SCREENING EXPERT

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.6082 mL	13.0412 mL	26.0824 mL
5 mM	0.5216 mL	2.6082 mL	5.2165 mL
10 mM	0.2608 mL	1.3041 mL	2.6082 mL
50 mM	0.0522 mL	0.2608 mL	0.5216 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Chaikuad A, et al. An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f]quinazoline-2-carbimides (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481